Merck disclosed that adding Welireg (belzutifan) to an existing Keytruda regimen did not produce a significant improvement in newly diagnosed patients with advanced kidney cancer. The company framed the readout as a setback for what had been positioned as a potential expansion of Welireg’s use in first-line settings. The failure matters for treatment sequencing in advanced renal cell carcinoma, where combination strategies can reshape standard-of-care if endpoints are met. It also affects Merck’s broader portfolio planning for Welireg and the economics of further trial investments. Analysts will likely re-evaluate competitive positioning across PD-1-based regimens versus alternative combination approaches, especially in markets where pricing and access pressures increase the importance of clear clinical differentiation.